The European Medicines Agency reports hundreds of fake profiles and advertisements, especially for diabetes and weight-loss medicines.
62% confidence
HealthEuropean Union
Omissions
The exact figure of 'hundreds' of fake profiles and advertisements does not appear explicitly in the sources retrieved; the EMA/HMA statement and secondary reporting confirm the phenomenon (fake profiles and adverts, sharp rise) but the precise count could not be independently verified.
The EMA warning was a joint EMA/HMA statement (4 September 2025) and several national competent authorities (e.g. HPRA in Ireland) also issued parallel requests to platforms such as Meta and Shopify; the claim attributes the report solely to EMA.
Sources describing the warning were published in September 2025, i.e. before the 2026-10-05 session date, so the MEP could have known them.
PrimaryAIFA (Italian Medicines Agency) — EMA/HMA joint statement on falsified GLP-1 medicinesIn recent months there has been a sharp rise in the number of illegal medicines marketed as GLP-1 receptor agonists such as semaglutide, liraglutide and tirzepatide for weight loss and diabetes. These products, often sold via [fraudulent websites and social media].